Wei-Jiao Zhan,
Jian-Feng Zhu,
Ying Zhang
Department of Ophthalmology, Linyi People's Hospital, Linyi, Shandong, 276000, China;
For correspondence:- Ying Zhang
Email: yingzhang4455@hotmail.com Tel:+865398078282
Received: 19 June 2016
Accepted: 9 June 2017
Published: 31 July 2017
Citation:
Zhan W, Zhu J, Zhang Y.
Inhibitory effect of puerarin on proliferation of retinoblastoma cells: An in-vitro study. Trop J Pharm Res 2017; 16(7):1615-1620
doi:
10.4314/tjpr.v16i7.21
© 2017 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Abstract
Purpose: To investigate the anti-proliferative effect of puerarin on retinoblastoma cells.
Methods: The effect of puerarin was examined on human retinoblastoma Y79 cells using cell proliferation assays and reverse transcription-polymerase chain reaction (RT-PCR). The effect of puerarin on the cell cycle was also investigated. Western blot and RT-PCR analyses were also performed to identify the putative mechanism of action.
Results: The results showed that cell viability was suppressed by puerarin in a concentration-dependent manner with a half-maximal inhibitory concentration (IC50) of 0.184 ± 0.034 μmol/L. Moreover, puerarin increased the proportion of cells in G1 phase from 42.6 ± 3.1 to 62.83 ± 4.1, 75.76 ± 3.4 and 91.33 ± 5.1 % in a concentration-dependent manner at concentrations of 0.1, 0.2, and 0.4 μmol/L, respectively. The results also indicate that Bmi-1 mRNA and protein levels decreased after puerarin treatment. Additionally, flow cytometry data showed that Bmi-1 knock-down through siRNA resulted in G1-cell cycle arrest. The proportion of cells in G1 were 51.2 ± 2.5 and 71.4 ± 4.5 % for control and Bmi-1 siRNA-treated groups, respectively.
Conclusions: The results show that puerarin exert suppressive effects on human retinoblastoma Y79 cells and therefore may find application in the treatment of intraocular tumor.
Keywords: Cancer, Puerarin, Retinoblastoma Y79 cells, mTOR inhibition, Intraocular tumor